Author Interviews, Gastrointestinal Disease, Hepatitis - Liver Disease, Weight Research / 07.05.2025
DDW25: GLP-1 Receptor Agonists May Result in Better Liver Outcomes than Bariatric Surgery in Obese Patients
[caption id="attachment_68344" align="alignleft" width="200"] Dr. Gernhard[/caption]
MedicalResearch.com Interview with:
Dr. Katilyn Gernhard DO
Internal Medicine Resident
Allegheny Health Network Pittsburgh
MedicalResearch.com: What is the background for this study?
Response: The background for this study is the steadily rising prevalence of obesity in the United States, which has been accompanied by an increase in related comorbid conditions, including Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Bariatric surgery and GLP-1 receptor agonists are two commonly used treatment options to address obesity and its associated complications.
While both have demonstrated benefits in weight loss and metabolic improvement, there has been limited direct comparison of their effectiveness specifically in patients with MASLD. Our study aimed to address this gap by comparing clinical outcomes in patients with MASLD treated with GLP-1 receptor agonists versus those treated with bariatric surgery.
Dr. Gernhard[/caption]
MedicalResearch.com Interview with:
Dr. Katilyn Gernhard DO
Internal Medicine Resident
Allegheny Health Network Pittsburgh
MedicalResearch.com: What is the background for this study?
Response: The background for this study is the steadily rising prevalence of obesity in the United States, which has been accompanied by an increase in related comorbid conditions, including Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Bariatric surgery and GLP-1 receptor agonists are two commonly used treatment options to address obesity and its associated complications.
While both have demonstrated benefits in weight loss and metabolic improvement, there has been limited direct comparison of their effectiveness specifically in patients with MASLD. Our study aimed to address this gap by comparing clinical outcomes in patients with MASLD treated with GLP-1 receptor agonists versus those treated with bariatric surgery.